Panion & Bf Biotech (TPE:1760) Accounts Payable: NT$163 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:1760 Panion & Bf Biotech Inc TPE:1760
74 GF Score
Price NT$61.10
GF Value NT$96.05
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Panion & Bf Biotech Accounts Payable?

Panion & Bf Biotech TPE:1760 74 Accounts Payable is NT$163 Mil as of Dec. 2025. GuruFocus rates TPE:1760 with a GF Score™ of 74/100 and a GF Value™ of NT$96.05 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Panion & Bf Biotech's Accounts Payable for the quarter that ended in Dec. 2025 was NT$163 Mil.

Panion & Bf Biotech's quarterly Accounts Payable declined from Jun. 2025 (NT$163 Mil) to Sep. 2025 (NT$162 Mil) but then increased from Sep. 2025 (NT$162 Mil) to Dec. 2025 (NT$163 Mil).

Panion & Bf Biotech's annual Accounts Payable increased from Dec. 2023 (NT$133 Mil) to Dec. 2024 (NT$153 Mil) and increased from Dec. 2024 (NT$153 Mil) to Dec. 2025 (NT$163 Mil).

Panion & Bf Biotech Accounts Payable Related Terms

Panion & Bf Biotech Accounts Payable Historical Data

* Premium members only.

The historical data trend for Panion & Bf Biotech's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Panion & Bf Biotech Accounts Payable Chart

Panion & Bf Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 130.23 125.27 133.46 153.28 162.55

Panion & Bf Biotech Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 153.28 150.26 162.56 161.51 162.55
TPE:1760
74GF Score
Panion & Bf Biotech Inc TPE:1760
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Panion & Bf Biotech Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of NT$163 Mil mean?
Panion & Bf Biotech (TPE:1760) has a Accounts Payable of NT$163 Mil as of Dec. 2025. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Panion & Bf Biotech and its competitors.
Is Panion & Bf Biotech's Accounts Payable too high?
Panion & Bf Biotech's current Accounts Payable is NT$163 Mil. Overall, Panion & Bf Biotech has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Panion & Bf Biotech's Accounts Payable compare to VRTX and REGN?
Panion & Bf Biotech's Accounts Payable of NT$163 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Drug Manufacturers company?
A good Accounts Payable depends on the Drug Manufacturers industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Panion & Bf Biotech and its competitors. Panion & Bf Biotech's current Accounts Payable is NT$163 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panion & Bf Biotech stock overvalued right now?
Based on GuruFocus' analysis, Panion & Bf Biotech (TPE:1760) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$96.05, compared to a current price of NT$61.10 — trading 36.4% below its estimated fair value. The current Accounts Payable is NT$163 Mil. Panion & Bf Biotech's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Panion & Bf Biotech (TPE:1760), the current Accounts Payable is NT$163 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Panion & Bf Biotech (TPE:1760) Overvalued in 2026?

Based on GuruFocus' analysis, Panion & Bf Biotech stock appears to be undervalued. The current stock price of NT$61.10 is trading 36.4% below its estimated GF Value™ of NT$96.05. GuruFocus considers Panion & Bf Biotech to be Significantly Undervalued.

Key valuation signals for TPE:1760:

  • Accounts Payable: NT$163 Mil
  • GF Value™: NT$96.05 vs. price of NT$61.10 (36.4% below fair value)
  • GF Score™: 74/100 with 4 warning signs

No single metric tells the full story. See the TPE:1760 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Panion & Bf Biotech Business Description

Address No. 3, Park Street, 16th Floor, Nangang District, Taipei, TWN, 11503
Panion & Bf Biotech Inc operates as a biotech and pharmaceutical company. The company, along with its subsidiaries, is mainly engaged in the manufacture and sales of pharmaceutical, cosmeceutical, diagnostic, medical device, and active pharmaceutical ingredients. It has four core business groups: disease treatment, disease prevention, disease diagnosis, and delayed aging. It has geographic segments in Taiwan; China, Hong Kong, and Macau; the USA; and Korea. It generates a majority of its revenue from the Taiwan segment. Product-wise the firm generates the majority of its revenue from Pharmaceutical products.
74GF Score

Get the complete analysis for TPE:1760

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$61.10
Price
NT$96.05
GF Value